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Abstract: Conotoxins are a pool of disulfide-rich peptide neurotoxins produced by cone snails for
predation and defense. They are a rich reservoir of novel ligands for ion channels, neurotransmitter
receptors and transporters in the nervous system. In this study, we identified a novel conotoxin
component, O-conotoxin GeXXVIIA, from the venom of Conus generalis. The native form of this
component is a disulfide-linked homodimer of a 5-Cys-containing peptide. Surprisingly, our
electrophysiological studies showed that, in comparison to the folded monomers, the linear peptide
of this toxin had the highest inhibitory activity at the human α9α10 nicotinic acetylcholine receptor
(nAChR), with an IC50 of 16.2 ± 1.4 nM. The activities of the N-terminal and C-terminal halves
of the linear toxin are markedly reduced compared with the full-length toxin, suggesting that the
intact sequence is required to potently inhibit the hα9α10 nAChR. α9α10 nAChRs are expressed not
only in the nervous system, but also in a variety of non-neuronal cells, such as cochlear hair cells,
keratinocytes, epithelial and immune cells. A potent inhibitor of human α9α10 nAChRs, such as
GeXXVIIA, would facilitate unraveling the functions of this nAChR subtype. Furthermore, this
unusual nAChR inhibitor may lead to the development of novel α9α10 nAChR-targeting drugs.
Keywords: conotoxin; O-superfamily; nicotinic receptor; α9α10; linear peptide
1. Introduction
The predatory cone snails (genus Conus) use their venoms as a weapon for predation and
defense [1]. Based on their prey, cone snails are classified into fish-, mollusk-, or worm-hunting species,
implying that their predation venoms may be largely different. Under the defensive evolutionary
pressure, all cone snails have also developed defensive venoms against predators [2,3]. No matter what
the purpose is, their venoms are primarily composed of an array of disulfide-rich peptides (conotoxins)
that target membrane ion channels and neurotransmitter receptors in the nervous system [4]. As the
number of conotoxin components is estimated to be in excess of 200,000, they are considered as a
reservoir for novel drug leads for neuroscience research and disease treatment [5–7]. For example,
ω-conotoxin MVIIA isolated from C. magus acts as a selective N-type Ca2+ channel inhibitor and has
been developed as an analgesic drug commercially known as Ziconotide or Prialt [8–10].
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Conotoxins are produced initially as gene-encoded polypeptide precursors and then maturated
through proteolytic cleavages, and often post-translational modifications. Based on the signal
peptide sequences of conotoxin precursors, the highly variable conotoxins are grouped into different
superfamilies [11]. However, conotoxins belonging to the same superfamily do not necessarily have
the same cysteine framework or functional target. One remarkable example is the O-superfamily
conotoxins that include Ca2+ channel-inhibiting ω-conotoxins, K+ channel-inhibiting κ-conotoxins,
Na+ channel-modifying δ-conotoxins, and Na+ channel-inhibiting µO-conotoxins [12].
Nicotinic acetylcholine receptors (nAChRs) are key in transmitting signals in the central and
peripheral nervous systems, opening a cation-selective pore upon the binding of acetylcholine (ACh) to
the extracellular domain [13]. nAChRs exist as homo- or hetero-pentameric channels and 17 subunits
have been recognized in vertebrate species (α1–α10, β1–β4, γ, δ, and ε). The skeletal muscle nAChR
subtype is composed of α1, β1, δ, and ε (adult isoform) or γ (fetal isoform) subunits at 2:1:1:1 ratio.
In contrast, neuronal nAChR subtypes are composed of only α and β subunits except for α7, α9, and
α10 subunits, which can form functional receptors without the participation ofβ subunits. Each nAChR
subtype has distinct tissue expression, pharmacological properties and physiological functions [14].
Although the heteromericα9α10 nAChR is generally characterized as neuronal, it is also expressed
in non-neuronal cells such as cochlear hair cells, keratinocytes, pituitary pars tuberalis, epithelial and
immune cells [15,16]. Investigation of the physiological roles of the α9α10 subtype would be greatly
facilitated by potent inhibitors of the human (h) α9α10 nAChR. In this study, we identified a novel
5 Cys-containing conotoxin from the venom of Conus generalis. The precursor sequence of this toxin
demonstrated that it is a member of the O1-superfamily. Although the native form of this toxin is a
disulfide-linked homodimer, surprisingly the linear peptide of this toxin is a potent inhibitor of hα9α10
nAChR, with an IC50 of 16.2 ± 1.4 nM. This novel nAChR inhibitor may lead to the development of
novel α9α10 nAChR-targeting drugs.
2. Results
2.1. Purification and Identification of a Five-Cys-Containing Component from the Venom of Conus generalis
The separation of the C. generalis crude venom on a C18 semi-preparative reverse-phase HPLC
column gave a series of peaks (Figure 1a). One minor peak, apart from two major peaks that have
been studied previously [17,18], was focused in this study. A secondary separation using a C18
analytical column (Figure 1b) revealed that there are three components in this minor peak, with
the second having a molecular mass of 9695 Da. Interestingly, reduction of this component with
dithiothreitol (DTT) changed its molecular mass to 4853 Da (Figure 1c), indicating that this component
is also a disulfide-linked homodimer, similar to αD-GeXXA [18]. Subsequently, alkylation with
N-ethylmaleimide (NEM) of the reduced monomeric peptide increased the molecular mass to 5479 Da,
which confirmed the presence of five Cys residues in this polypeptide chain (Figure 1d). The odd
number of Cys residues is unique for conotoxins, which prompted us to investigate further.




Figure  1.  Purification  and  identification  of  O‐conotoxin  GeXXVIIA  from  Conus  generalis.  (a) 
Purification  of  crude  venom  extracted  from  C.  generalis  (shown  in  inset)  on  a  ZORBAX  C18 
semi‐preparative  column.  The  asterisk  indicates  the  fraction  containing  GeXXVIIA.  The  elution 
gradient  is  0–50%  Buffer  B  for  0–50 min with  a  flow  rate  of  0.5 mL/min.  (b)  Analytical  scale 
purification of the GeXXVIIA‐containing  fraction  from panel  (a) on a C18 reverse‐phase analytical 
column. The peak with a molecular mass of 9695 Da is that of GeXXVIIA. The elution gradient is 10–
30% Buffer B  for 0–10 min and 30–39% Buffer B  for 10–37 min with a  flow rate of 0.5 mL/min.  (c) 
Purification of the reduced GeXXVIIA after being treated with DTT on a C18 reverse‐phase analytical 
column. The elution gradient  is 10–45% Buffer B  for 0–35 min with a  flow rate of 0.5 mL/min.  (d) 




gave  a  partial  N‐terminal  sequence  of  ALMSTGTNYRLP(T/K)(T/K)CRxSG,  where  x  is  an 
unidentified residue. Then, gene specific primers were designed, based on this N‐terminal sequence, 
and  3’‐RACE was  carried out  to obtain  the  3’‐partial  cDNA  sequence. The  amino  acid  sequence 
deduced  from  the  3’‐partial  cDNA  sequence  was  highly  homologous  to  the  sequence  of 
O1‐superfamily conotoxin Mik41 [19]. Therefore, we took advantage of the known cDNA sequence 
of Mik41 and designed an upstream primer to amplify the 5’‐partial cDNA sequence of this toxin. 
The  complete  cDNA  sequence  of  this  toxin was  obtained  by  overlapping  the  3’‐partial  and 
5’‐partial  cDNA  sequences  (Figure  2a).  The  cDNA‐encoded  precursor  has  a  typical  conotoxin 
organization of 22‐residue signal peptide, 11‐residue pro‐peptide, and 41‐residue mature toxin. The 
conserved signal peptide clearly indicates that this toxin belongs to the O1‐superfamily. Additionally, 





toxin GeXXVIIA. The molecular mass of  the  cDNA‐deduced mature  toxin,  4809.6 Da,  is  slightly 
different from the mass of the reduced natural toxin, which is likely due to sequence polymorphism 
or post‐translational modifications. 
Figure 1. Purification and identification of O-conotoxin GeXXVIIA from Conus generalis. (a) Purification
of crude venom extracted fro C. generalis (shown in inset) on a ZORBAX C18 semi-preparative column.
The asterisk indicates the fraction containing GeXXVIIA. The elution gradient is 0–50% Buffer B for
0–50 min with a flow rate of 0.5 mL/min. (b) Analytical scale purification of the GeXXVIIA-containing
fraction from panel (a) on a C18 reverse-phase analytical column. The peak with a molecular mass of
9695 Da is that of GeXXVIIA. The elution gradient is 10–30% Buffer B for 0–10 min and 30–39% Buffer
B for 10–37 mi with a fl w r te of 0.5 mL/min. (c) Purification of the reduced GeXXVIIA after being
treated with DTT on a C18 reverse-phase analytical column. The elution gradient is 10–45% Buffer B
for 0–35 min with a flow rate of 0.5 mL/min. (d) Purification of the GeXXVIIA peptide after being
alkylated with NEM on a C18 reverse-phase analytical column. The elution gradient is the same as that
of panel (c).
2.2. Sequence Determination and cDNA Cloning
The reduced and alkylated monomeric peptide was first applied to Edman sequencing, which
gave a partial N-terminal sequence of ALMSTGTNYRLP(T/K)(T/K)CRxSG, where x is an unidentified
residue. Then, gene specific primers were designed, based on th s N-terminal s quence, a d 3’-RACE
was carried out to obtain the 3’-partial cDNA sequence. The amino acid sequence deduced from
the 3’-partial cDNA sequence was highly homologous to the sequence of O1-superfamily conotoxin
Mik41 [19]. Therefore, we took advantage of the known cDNA sequence of Mik41 and designed an
upstream primer to amplify the 5’-partial cDNA sequence of this toxin.
The complete cDNA sequence of this toxin was obt ined by overlapping the 3’-partial and
5’-partial cDNA sequences (Figure 2a). The cDNA-encoded precursor has a typical conotoxin
organization of 22-residue signal peptide, 11-residue pro-peptide, and 41-residue mature toxin.
The conserved signal peptide clearly indicates that this toxin belongs to the O1-superfamily.
Additionally, the precursor equence of this toxin is similar to two other O1-superfamily conotoxins,
Mik41 and GeXIVA (Figure 2b) [19,20]. However, the new toxin has an additional 13 amino acid
residues at the N-terminus of the mature peptide and 5 Cys residues compared to 6 for MiK41 and 4
for GeXIVA.
The cysteine framework of this conotoxin is different from other conotoxins that often contain
even numbers of Cys residues. Therefore, we numbered this framework as XXVII and named this
toxin GeXXVIIA. The molecular mass of the cDNA-deduced mature toxin, 4809.6 Da, is slightly
different from the mass of the reduced natural toxin, which is likely due to sequence polymorphism or
post-translational modifications.




Figure  2.  cDNA  sequence  of  O‐GeXXVIIA.  (a)  The  cDNA  sequence  of  GeXXVIIA  and  the 
cDNA‐encoded precursor  sequence. The  coding  region  of  cDNA  is  shown  in  capital  letters. The 
signal peptide sequence is shadowed, and the mature peptide sequence is underlined. Between the 
signal sequence and mature toxin region is the pro‐peptide region. * represents the stop codon. (b) 




low  amount  of  the  native GeXXVIIA, we  sought  to  chemically  synthesize  the  linear  peptide  of 
GeXXVIIA and then refold it in vitro. However, the regular air oxidation and glutathione oxidation 
conditions failed  to produce a peak with  the expected molecular mass. We managed  to have  two 
disulfide bonds  formed  in each peptide only  in  the condition of 400 mM arginine, with DTT and 






reverse‐phase  analytical  column. The  elution  is  isocratic  at  22% Buffer B with  a  flow  rate  of  0.5 
mL/min. The molecular masses of  these  four  isomers  are  the  same,  4807 Da,  indicating  that  two 
disulfide bonds are formed in each isomer. (b) The inhibition of 5 μM GeXXVIIA‐m1, ‐m2, ‐m3, and 
‐m4  on  ACh‐evoked  peak  current  amplitude  mediated  by  hα3β2,  hα3β4,  hα7,  hα4β4,  hα4β2, 
hα9α10, and rodent (r) α1β1εδ nAChRs (n = 1 oocyte for each nAChR subtype). 
Figure 2. cDNA sequence of O-GeXXVIIA. (a) The cDNA sequence of GeXXVIIA and the
cDNA-encoded precursor sequence. The coding region of cDNA is shown in capital letters. The signal
peptide sequence is shadowed, and the mature peptide sequence is underlined. Between the signal
sequence and mature toxin region is the pro-peptide region. * represents the stop codon. (b) Alignment
of the precursor sequences of GeXXVIIA, Mik41 [19], and GeXIVA [20]. Mature toxin sequences are
underlined with the Cys residues highlighted in bold.
2.3. Oxidative Refolding of GeXXVIIA
The unique sequence of GeXXVIIA motivated us to investigate its biological activity. Due to
the low amount of the native GeXXVIIA, we sought to chemically synthesize the linear peptide of
GeXXVIIA and then refol it in vitro. However, the regular air oxidation and glutat ione oxidation
conditions failed to prod e a peak with the xpected molecular mass. We managed to have two
disulfide bonds formed in each peptide only in the con ition of 400 mM arginine, with DTT and
oxidized DTT as reducing-oxidizing pair reagents, and four different isomers with the same molecular
mass were formed (Figure 3a). No dimeric product was observed, probably because the formation of
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low  amount  of  the  native GeXXVIIA, we  sought  to  chemically  synthesize  the  linear  peptide  of 
GeXXVIIA and then refold it in vitro. However, the regular air oxidation and glutathione oxidation 
conditions failed  to produce a peak with  the expected molecular mass. We managed  to have  two 
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reverse‐phase  analytical  column. The  elution  is  isocratic  at  22% Buffer B with  a  flow  rate  of  0.5 
mL/min. The molecular masses of  these  four  isomers  are  the  same,  4807 Da,  indicating  that  two 
disulfide bonds are formed in each isomer. (b) The inhibition of 5 μM GeXXVIIA‐m1, ‐m2, ‐m3, and 
‐m4  on  ACh‐evoked  peak  current  amplitude  mediated  by  hα3β2,  hα3β4,  hα7,  hα4β4,  hα4β2, 
hα9α10, and rodent (r) α1β1εδ nAChRs (n = 1 oocyte for each nAChR subtype). 
Figure 3. Preparati n and nAChR-inhibit ry activities of the onomeric isomers of GeXXVIIA.
(a) Separation of four GeXXVIIA monomeric isomers (m1, m2, m3, and m4) refolded in vitro on
a C18 reverse-phase analytical column. The elution is isocratic at 22% Buffer B with a flow rate of
0.5 mL/min. The molecular masses of these four isomers are the same, 4807 Da, indicating that two
disulfide b ds are f rmed in each isomer. (b) The inhibition of 5 µM GeXXVIIA-m1, -m2, -m3, and
-m4 on ACh-evoked peak current amplitude mediated by hα3β2, α3β4, hα7, hα4β4, hα4β2, hα9α10,
and rodent (r) α1β1εδ nAChRs (n = 1 oocyte for each nAChR subtype).
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2.4. Inhibitory Effects of GeXXVIIA Monomeric Isomers on nAChRs
It has been reported previously that GeXIVA, which has similar sequence to the C-terminal
sequence of GeXXVIIA, inhibits ACh-evoked current of nAChRs in a structure-insensitive manner [20].
Therefore, we tested the four monomeric isomers of GeXXVIIA (GeXXVIIA-m1 to -m4) at various
nAChR subtypes heterologously expressed in Xenopus laevis oocytes, initially at 5 µM. Surprisingly, all
GeXXVIIA isomers inhibited nAChR-mediated currents. Although the inhibition at hα3β2, α3β4, α7,
and α4β4 nAChR subtypes was modest, these monomers all potently inhibited rodent (r) α1β1εδ and
hα9α10 nAChR subtypes (Figure 3b).
2.5. Inhibition Activity of the Linear GeXXVIIA and Its Two Fragments
The results above demonstrated that the inhibitory activity of GeXXVIIA on different nAChR
subtypes was not greatly affected by the different disulfide linkages in these isomers, similar to that of
GeXIVA [20]. We then prepared a disulfide-free linear peptide of GeXXVIIA by modifying the Cys
residues with iodoacetamide (IAA) (Figure 4a, left panel), and tested its activity at the two preferred
subtypes, rα1β1εδ and hα9α10 nAChRs. Remarkably, the same concentration (5 µM) of the linear
GeXXVIIA (GeXXVIIA-L) retained potent inhibitory activity on the ACh-evoked currents of these two
nAChR subtypes (Figure 4b), which further highlighted that the folding of the peptide is not required
for the interaction with nAChRs. This result also raised the possibility that the binding of the linear
GeXXVIIA peptide with nAChR is only dependent on the sequence of the peptide.
In order to narrow down the critical sequence of GeXXVIIA-L responsible for the
nAChR-inhibitory activity, we took advantage of the presence of the only two Asp residues in this toxin,
and digested the linear GeXXVIIA with Asp-N protease into GeXXVIIA-L-Nter and GeXXVIIA-L-Cter
fragments (Figure 4a). At 5 µM, the GeXXVIIA-L-Nter fragment strongly inhibited both rα1β1εδ
and hα9α10 nAChR subtypes (Figure 4c), whereas the GeXXVIIA-L-Cter inhibited more strongly the
hα9α10 nAChR (>90% inhibition) than the rα1β1εδ subtype (~30% inhibition) (Figure 4d). These
results suggest that the N-terminal part of GeXXVIIA-L retains more nAChR inhibition activity than
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Figure 4. Preparation and nAChR-inhibitory activities of the linear GeXXVIIA and its N- and C-terminal
fragments. (a) Left panel: Preparation of the linear peptide of GeXXVIIA (GeXXVIIA-L) alkylated
with IAA on a C18 reverse-phase analytical column. Its molecular mass is 5096 Da. The elution
gradient is 15–37% Buffer B for 0–22 min with a flow rate of 0.5 mL/min. Right panel: Two fragments
were obtained after the digestion of GeXXVIIA-L by Asp-N protease. The elution gradient is 5–38%
acetonitrile for 0–33 min with a flow rate of 0.5 mL/min. The N-terminal (Nter) nd C-termin l (Cter)
fragm nts of GeXXVIIA-L ave a molecular mass of 3070 Da and 1598 Da, resp ctively. B low are
the sequences of GeXXVIIA-L, Nter and Cter peptides, with the IAA-blocked Cys residues shown
in red. (b–d) Superimposed ACh-evoked currents mediated by rα1β1εδ and hα9α10 nAChRs in the
absence (C, control) and the presence of 5 µM different GeXXVIIA peptides (P). Arrows (H) indicate
ACh application. The peptides are GeXXVIIA-L (b), GeXXVIIA-L-Nter (c), and GeXXVIIA-L-Cter (d).
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2.6. IC50 Values of the GeXXVIIA-L and GeXXVIIA-L-Nter
At 5 µM, GeXXVIIA-L, GeXXVIIA-L-Nter, and -Cter fragments inhibited hα9α10 nAChR by >90%
(Figure 4b–d), whereas at 300 nM, their inhibition levels diverged: the full-length linear GeXXVIIA
still strongly inhibited hα9α10 nAChR (>90%), but the two fragments produced only ~55% inhibition
(Figure 5a). Interestingly, when the folded monomer GeXXVIIA-m1 was tested at 300 nM as a reference,
it gave a similar degree of inhibition as the two fragments of the linear peptide, but weaker than the
full-length GeXXVIIA-L. Comparison between the inhibition levels of GeXXVIIA-m1 and GeXXVIIA-L
implies that the disulfide linkage in the peptide decreased the inhibitory activity, on hα9α10 nAChR
at least.
To obtain the quantitative potencies of the linear GeXXVIIA and GeXXVIIA-L-Nter, we measured
their IC50 values at rα1β1εδ and hα9α10 nAChRs (Figure 5b). At rα1β1εδ nAChR, the full-length
GeXXVIIA-L peptide gave an IC50 value of 774 ± 48 nM, whereas the GeXXVIIA-L-Nter fragment
had an IC50 of 2.19 ± 0.24 µM, only about three-fold higher than GeXXVIIA-L, suggesting that
the C-terminal part of the peptide does not contribute much to the interaction with this nAChR
subtype. Unexpectedly, GeXXVIIA-L was highly potent at hα9α10 nAChR, with an IC50 of
16.2 ± 1.4 nM. Moreover, the potency of GeXXVIIA-L-Nter at this subtype was 14-fold weaker,
with an IC50 of 222.5 ± 14.0 nM. The more dramatic difference between the full-length GeXXVIIA-L
and GeXXVIIA-L-Nter suggests that the C-terminal part participates in the interaction with hα9α10




At 5 μM, GeXXVIIA‐L, GeXXVIIA‐L‐Nter, and  ‐Cter  fragments  inhibited hα9α10 nAChR by 
>90%  (Figure  4b–d), whereas  at  300  nM,  their  inhibition  levels  diverged:  the  full‐length  linear 
GeXXVIIA  still  strongly  inhibited hα9α10 nAChR  (>90%), but  the  two  fragments produced only 
~55%  inhibition (Figure 5a). Interestingly, when the folded monomer GeXXVIIA‐m1 was tested at 
300  nM  as  a  reference,  it  gave  a  similar degree  of  inhibition  as  the  two  fragments  of  the  linear 
peptide, but weaker than the full‐length GeXXVIIA‐L. Comparison between the inhibition levels of 
GeXXVIIA‐m1  and GeXXVIIA‐L  implies  that  the  disulfide  linkage  in  the  peptide  decreased  the 
inhibitory activity, on hα9α10 nAChR at least. 
To  obtain  the  quantitative  potencies  of  the  linear  GeXXVIIA  and  GeXXVIIA‐L‐Nter,  we 






222.5  ±  14.0  nM.  The  more  dramatic  ifference  between  the  full‐length  G XXVIIA‐L  and 
GeXXVIIA‐L‐Nter  suggests  that  the C‐terminal  p rt  participates  in  the  interaction with  hα9α10 
nAChR more than with rα1   . 
 
















indicates  that  GeXXVIIA‐L  is  a  non‐competitive  antagonist  at  hα9α10  nAChR.  Furthermore, 
GeXXVIIA‐L  (16.2  nM)  inhibition  of ACh‐evoked  currents  at  hα9α10  nAChR was  similar  at  all 
membrane potentials tested (45.6 ± 7.3% at −120 mV (n = 5), 44.9 ± 5.6% at −80 mV (n = 9), and 45.6 ± 
Figure 5. Antagonist potencies of GeXXVIIA-L and GeXXVIIA-L-Nter at the rodent α1β1εδ and
human α9α10 nAChRs. (a) Inhibition of ACh-evoked peak current amplitude mediated by rα1β1εδ
and hα9α10 nAChRs by GeXXVIIA-m1, GeXXVIIA-L, GeXXVIIA-L-Nter, and GeXXVIIA-L-Cter at
5 µM (n = 1 oocyte) and 300 nM (n = 3–7 oocytes) peptide concentrations. Error bars indicate SEM.
(b) Concentration-response curves obtained for GeXXVIIA-L and GeXXVIIA-L-Nter inhibition of
rα1β1εδ and hα9α10 nAChRs expressed in Xenopus laevis oocytes. Full-length GeXXVIIA-L exhibits
potent inhibitory activity at hα9α10 receptors with an IC50 of 16.2 ± 1.4 nM (n = 4–8 oocytes for each
data point).
2.7. Mechanism of Action of GeXXVIIA-L at hα9α10 nAChR
The high potency an the unique working conforma (linear peptide) of GeXXVIIA at
hα9α10 nAChR encouraged us to explore its mechanism of action. To ascertain whether it
binds to the orthosteric ACh binding sit , we etermined GeXXVIIA-L inhibition (appli d at IC50
of 16.2 nM) of the hα9α10 nAChR-mediated currents evoked by different ACh concentrations.
The ACh-evoked current amplitude was inhibited by 43.6 ± 1.4% (n = 10) when evoked with 6 µM
ACh, 46.9 ± 2.4% (n = 11) when evoked with 30 µM ACh and 46.7 ± 2.9% (n = 9) when evoked with
100 µM ACh. The insurmountable inhibition of hα9α10 nAChR by GeXXVIIA-L when raising the
ACh concentration indicates that GeXXVIIA-L is a non-competitive antagonist at hα9α10 nAChR.
Furthermore, GeXXVIIA-L (16.2 nM) inhibition of ACh-evoked currents at hα9α10 nAChR was similar
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at all membrane potentials tested (45.6 ± 7.3% at −120 mV (n = 5), 44.9 ± 5.6% at −80 mV (n = 9), and
45.6 ± 8.1% at −40 mV (n = 4)). These results indicate that GeXXVIIA-L inhibition of hα9α10 nAChR
is voltage-independent, suggesting that the peptide does not enter the membrane electric field and is
unlikely to be an open channel pore blocker.
3. Discussion
Conotoxins are well known for their structural and functional diversity. In this study, we identified
a novel conotoxin GeXXVIIA from the South China Sea mollusk C. generalis and classified it as a member
of the O1-superfamily conotoxins. However, the mature peptide sequence of GeXXVIIA contains
five Cys residues, which is distinct from the cysteine framework VI/VII (C–C–CC–C–C) in most of
the O-superfamily conotoxins [12]. Comparison with the cDNA sequence of Mik41 suggests that the
cysteine framework of GeXXVIIA may well be the result of a point mutation that changes the codon
of the fourth Cys (TGC) in Mik41 into a codon of Arg (CGC) in GeXXVIIA [19]. The random point
mutation in conotoxin genes has been found to be one of the mechanisms for conotoxin diversity [21].
Due to this unique cysteine framework, we propose that GeXXVIIA represents a new branch of
the O1-superfamily.
It is uncommon for conotoxins to have odd number of Cys residues, as conotoxins are often
disulfide-linked monomers, whereas an uneven number of Cys residues suggests the existence of
interchain disulfide bond. Other conotoxins containing an odd number of Cys residues include TxXIIIA
(with five Cys residues in the short sequence TSDCCFYNCCC) and the con-ikot-ikot (with 13 Cys
residues in the mature sequence) [22,23]. Both of them form disulfide-linked homodimers, as believed
for the native GeXXVIIA. However, the elucidation of the dimerization linkage remains a challenge.
So far, the linkage is known only for two dimeric conotoxins, con-ikot-ikot and αD-GeXXA, by X-ray
structure determination in both cases [18,24]. However, the very low abundance of the natural dimeric
GeXXVIIA is a major obstacle for the structural study of this toxin.
Following the report of GeXIVA [20], we discovered that the monomeric GeXXVIIA has
nAChR-inhibitory activity. Furthermore, different disulfide linkages were found not to change much
the nAChR-inhibitory activity of GeXXVIIA (Figure 3), which is consistent with the properties of
GeXIVA [20]. As the predicted sequence of GeXIVA differs from GeXXVIIA sequence mainly by the
lack of N-terminal 13 residues, it appears that the basal nAChR-inhibitory activity of GeXXVIIA is
mediated by the C-terminal part analogous to GeXIVA. However, quantitative comparison of the toxin
activities suggests that the existence of the N-terminal extension in GeXXVIIA enhances the potency
and specificity on hα9α10 nAChR.
The α9α10 subtype nAChRs were originally characterized in cochlear hair cells where they
function in mediating synaptic transmission between the olivocochlear system and auditory hair
cells of the cochlea [25–27]. Other studies reported that α9α10 nAChRs are expressed in different
tissues, including dorsal root ganglia, skin, lymphocyte, sperm, and immune cells [28–32]. Potent
α9α10-specific antagonizing conotoxins, such as α-RgIA, α-Vc1.1 and the bead isomer of GeXIVA, have
been shown to provide long lasting relief in rat models of neuropathic pain, although the underlying
mechanism remains controversial [20,33–39]. Recent studies have also shown that the α9 subunit is
over-expressed in breast tumors [40]. Therefore, considering the physiological importance of hα9α10
nAChR, ligands with high potency on this nAChR subtype would be of great potential. However,
the development of hα9α10 nAChR-selective conotoxins is hindered by the fact that most of the
α9α10 subtype-specific conotoxins have only been studied on the rat nAChR subtype, examples
including α-RgIA, α-Vc1.1, αS-GVIIIA, and αO-GeXIVA (Table 1). Prior to this study, only αD-GeXXA
(IC50 = 28 nM) [18] and GeXIVA bead isomer (IC50 = 20 nM) [41] showed high potency at the hα9α10
subtype. The novel conotoxin GeXXVIIA identified in this study has a similarly high potency at
the hα9α10 subtype (IC50 = 16.2 nM). However, unlike the conotoxins discussed above, in which
their potency is dependent on the disulfide folding, GeXXVIIA is a more potent inhibitor as a
linear peptide. This unique property not only facilitates the synthesis and use of this toxin, but
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also suggests that GeXXVIIA has an unusual nAChR-inhibition mechanism. Indeed, the comparable
inhibition by GeXXVIIA-L tested with different ACh concentrations or at different membrane potentials
demonstrates that GeXXVIIA-L is neither a competitive antagonist, nor a channel pore blocker of
nAChR. Most likely, GeXXVIIA-L is a new class of nAChR allosteric inhibitor.
It is unusual among conotoxins that the linear GeXXVIIA is more potent than its folded
counterparts (Figure 5a). This suggests that the interaction between GeXXVIIA and α9α10 nAChR is
improved with an extended peptide of GeXXVIIA, most likely because the nAChR-binding sites in
GeXXVIIA are distributed along the sequence of this toxin. This is probably why both the two halves
of GeXXVIIA have diminished nAChR-inhibitory activities compared to the full-length toxin. In other
words, both the two halves of linear GeXXVIIA cooperatively contribute to the high potency of this
toxin. Given the unusual high content of basic residues (nine Arg and one Lys out of 41 residues) in the
GeXXVIIA sequence (Figure 2), it is highly likely that the electrostatic interaction with the nAChR acidic
residues plays a major role in binding. Consistent with this proposal, a strongly electronegative surface
was identified in the extracellular vestibule from the crystal structural study of α4β2 nAChR [42].
Identification of the binding site of GeXXVIIA on α9α10 nAChR may furnish valuable information in
understanding the gating mechanism of this receptor.
In summary, we have identified a novel O-superfamily conotoxin GeXXVIIA from the venom
of C. generalis. We discovered that the linear peptide of GeXXVIIA can strongly inhibit the activity
of the human α9α10 nAChR with an IC50 of 16.2 nM. Although nAChR may not be the target of the
native GeXXVIIA toxin that is a disulfide-linked homodimer, the high potency of its linear peptide on
hα9α10 nAChR per se is of great interest. These findings suggest an unusual inhibition mechanism
on nAChR, which merits further investigation, both for the understanding of nAChR structure and
function and for the development of novel nAChR inhibitors.




Name Conus Species Toxin Sequence
Species of
α9α10 nAChR IC50 (nM) Reference
O GeXXVIIA C. generalis ALMSTGTNYRLLKTCRGSGRYCRSPYDCRRRYCRRISDACV H. sapiens 16.2 This study
O GeXIVA C. generalis TCRSSGRYCRSPYDRRRRYCRRITDACV
R. norvegicus 4.6 [20]
H. sapiens 20.3 [41]
A RgIA C. regius GCCSDPRCRYRCR
R. norvegicus 1.5
[43]H. sapiens 494
A Vc1.1 C. victoriae GCCSDPRCNYDHPEIC * R. norvegicus 19 [33]
S GVIIIB C. geographus SGSTCTCFTSTNCQGSCECLSPPGCYCSNNGIRQRGCSCTCPGT * R. norvegicus 9.8 [44]






4. Materials and Methods
4.1. Toxin Isolation and Purification
Specimens of C. generalis were collected from the South China Sea, near the coast of Sanya,
Hainan Island, China. In order to extract the crude venom, the venom ducts were homogenized and
suspended in 0.1% (v/v) trifuoroacetic acid (TFA). After centrifugation at 12,000× g at 4 ◦C for 15 min,
the supernatant was collected and the pellet was stirred in 0.1% TFA for 30 min, then re-centrifuged.
Precipitates were pooled and re-extracted successively with 0.1% TFA in 20, 30, 40 and 50% acetonitrile.
Supernatants were combined, lyophilized, and stored at −20 ◦C.
To purify the conotoxins, the lyophilized crude venom was dissolved in Buffer A (0.1% TFA).
After centrifugation, the supernatant was applied on a ZORBAX C18 semi-preparative column
(9.4 × 250 mm, Agilent, Santa Clara, CA, USA) and eluted with a gradient of buffer B (0.1% TFA
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in 100% acetonitrile) using an Agilent 1100 HPLC system. Further purification was performed on a
ZORBAX C18 analytical column (4.6 × 250 mm, Agilent, Santa Clara, CA, USA).
4.2. Toxin Characterization and N-Terminal Sequencing
The purified conotoxin component was dissolved in the reduction buffer of 100 mM Tris-HCl,
pH 8.7 and 2 mM EDTA, and reduced with a 100-fold excess of dithiothreitol (DTT) at 37 ◦C for 1 h.
The reduced peptide was purified on a ZORBAX C18 analytical column (4.6 × 250 mm, Agilent, Santa
Clara, CA, USA). Thiol groups were alkylated with 10 mM N-ethylmaleimide (NEM) in the reduction
buffer at 37 ◦C in the dark for 0.5 h. The modified peptide was purified by a C18 reverse-phase column
on HPLC, and directly used for N-terminal sequencing on ABI 491A Procise® Protein Sequencing
System (Applied Biosystems, Foster City, CA, USA).
The mass spectrometry analyses of the native, reduced and S-alkylated toxins were performed
on a Q-trap mass spectrometer (Applied Biosystems, Foster City, CA, USA), using the scan type of
Enhanced MS. The apparatus was equipped with a TurboIonSpray source and operated in positive
ionization mode.
4.3. cDNA Cloning
Total RNA was extracted from homogenized venom duct tissues using Trizol Reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s protocol. Reverse transcription was carried out
using a universal oligo dT-containing adapter primer 5’-GGC CAC GCG TCG ACT AGT AC (dT)17-3’
(Superscript II Kit, Invitrogen, Carlsbad, CA, USA). The resulting cDNA was used as a template for
cDNA-cloning PCR.
Complete cDNA sequence of this toxin was obtained by overlapping the 3’- and 5’-partial cDNA
sequences. The 3’-partial cDNA was first amplified through two rounds of PCR. The first PCR
reaction was carried out using a degenerate oligonucleotide primer GSP1 (5’-GCNYTRATGTCN
ACNGGNACNAAYTAY-3’, Y: T/C, R: G/A, N: A/T/G/C), designed based on the N-terminal
sequence (ALMSTGTNY-) and an outer primer provided by the 3’-RACE kit (Takara, Dalian, China).
The second round of PCR amplification was carried out using the product of the first round PCR as
the template by pairing the upstream primer GSP2 (5’-ATGTCNACNGGNACNAAYTAY-3’), designed
based on the partial N-terminal sequence (-MSTGTNY-) with an inner primer provided by the kit.
The ~250 bp PCR products were ligated into pGEM-T Easy vector (Promega, Madison, WI, USA)
for sequencing.
Sequence comparison of the 3’-partial cDNA obtained above with other conotoxins showed that
the mature peptide sequence of this toxin displays a high degree of homology to that of O-superfamily
conotoxin Mik41 [19]. As the signal peptide of the O-superfamily is highly conserved, an upstream
primer SP1 (5’-CATCGTCAAGATGAAACTGACG-3’) was designed based on the known cDNA
sequence of Mik41. According to the 3’-partial sequence of GeXXVIIA, we designed a specific antisense
primer GSP3 (5’-CACAGGTATGGATGACTCAGG’-3’) corresponding to the 3’-untranslated region.
The 5’-partial cDNA of GeXXVIIA was amplified from the total cDNAs of C. generalis with these two
primers and ligated into pGEM-T Easy vector (Promega, Madison, WI, USA) for sequencing.
4.4. Peptide Synthesis and Refolding
The linear peptide of GeXXVIIA, with all 5 Cys residues unprotected, was synthesized by the
Chinese Peptide Company (Hangzhou, China). Oxidative folding of the purified linear peptide (20 µM)
was performed at 4 ◦C for one week in a buffer comprising 50 mM Tris-HCl, pH 8.0, 400 mM arginine,
0.02 mM DTT, and 0.3 mM oxidized DTT. The oxidized products were purified on a ZORBAX C18
HPLC analytical column (4.6 × 250 mm, Agilent) with isocratic elution. Each monomer component
was applied to a secondary HPLC purification.
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4.5. Peptide Alkylation and Digestion by Protease Asp-N
The synthesized linear GeXXVIIA was alkylated with 10 mM iodoacetamide (IAA) in 100 mM
Tris-HCl, pH 8.7, and 2 mM EDTA at 22 ◦C in the dark for 1 h. The alkylated linear peptide GeXXVIIA-L
was purified on a ZORBAX C18 HPLC analytical column (4.6 × 250 mm, Agilent). The digestion of
alkylated GeXXVIIA-L was carried out in 100 mM Tris-HCl, pH 8.5, using 3 µg/mL Asp-N (Sigma,
St Louis, MO, USA) at 37 ◦C for 18 h. The digested products were separated on a ZORBAX C18 HPLC
analytical column (4.6 × 250 mm, Agilent).
4.6. Oocyte Two-Electrode-Voltage Clamp Recordings
Oocyte preparation, RNA preparation, and expression of nAChR subunits in Xenopus oocytes
were performed as described previously [12]. All procedures were approved by the University of
Sydney Animal Ethics Committee. Plasmid constructs of rat (α1, β1, and δ), mouse (ε) and human
(α3, α4, α7, α9, α10, β2, and β4) nAChR subunits were linearized for in vitro mRNA synthesis using
mMessage mMachine transcription kit (AMBION, Forster City, CA, USA).
Stage V–VI Xenopus laevis oocytes were defolliculated with collagenase (Worthington Biochemical
Corp., Lakewood, NJ, USA) at room temperature (20–25 ◦C) for 1 h in OR-2 solution containing (in mM)
82.5 NaCl, 2 KCl, 1 MgCl2, and 5 HEPES at pH 7.4. Oocytes were injected with 5 ng cRNA for hα3β2,
α3β4, α4β2, α4β4, α7 or rodent α1β1δε nAChRs, and 35 ng cRNA for hα9α10 nAChR (concentration
confirmed spectrophotometrically and by gel electrophoresis) using glass pipettes. Oocytes were
incubated at 18 ◦C in sterile ND96 solution composed of (in mM) 96 NaCl, 2 KCl, 1 CaCl2, 1 MgCl2,
and 5 HEPES at pH 7.4, supplemented with 5% fetal bovine serum, 50 mg/L gentamicin (GIBCO,
Grand Island, NY, USA) and 10,000 U/mL penicillin-streptomycin (GIBCO, Grand Island, NY, USA).
Membrane currents were recorded from oocytes expressing nAChRs at room temperature, using
a GeneClamp 500B amplifier and pClamp9 software interface (Molecular Devices, Sunnyvale, CA,
USA) in a two-electrode voltage-clamp recording configuration (holding potential −80 mV). In a series
of experiments, the effect of different membrane potentials (−120, −80, and −40 mV) on GeXXVIIA
inhibition of hα9α10 nAChRs was tested. Voltage-recording and current-injecting microelectrodes
were pulled from GC150T-7.5 borosilicate glass (Harvard Apparatus Ltd., Holliston, MA, USA), giving
tip resistances of 0.3–1.5 MΩ when filled with 3 M KCl. Oocytes were perfused with ND96 solution at
a rate of 2 mL/min. Oocytes expressing hα9α10 nAChRs were incubated in 100 µM BAPTA-AM ~3 h
before recording and perfused with ND115 solution containing (in mM): 115 NaCl, 2.5 KCl, 1.8 CaCl2,
and 10 HEPES at pH 7.4.
Initially, oocytes were briefly washed with bath solution (ND96/ND115) followed by three
applications of acetylcholine (ACh) at half-maximal effective concentration (EC50) of 6 µM for hα3β2,
hα9α10 and hα4β4 nAChRs, 300 µM for hα3β4, 100 µM for hα7, 3 µM for hα4β2, and 1 µM for
rα1β1εδ nAChRs. Washout with bath solution was done for 3 min between ACh applications.
GeXXVIIA-L inhibition of hα9α10 nAChRs was also examined at different ACh concentrations as
indicated. Oocytes were incubated with peptides for 5 min with the perfusion system turned off,
followed by co-application of ACh and peptide with flowing bath solution. All peptide solutions were
prepared in ND96/ND115 + 0.1% bovine serum albumin. Peak current amplitude evoked by ACh was
measured before and following incubation with peptide in order to determine the effect on specific
nAChR subtype. Concentration-dependent response curves for antagonists were fitted by unweighted
nonlinear regression to the following logistic equation:
Ex = Emax XnH/(XnH + IC50nH), (1)
where Ex is the response, X is the antagonist concentration, Emax is the maximal response, nH is the slope
factor, and IC50 is the antagonist concentration giving half-maximal response. All electrophysiological
data were pooled (n = 4–11 oocytes for each data point) and represented as means ± standard error of
the mean (SEM). The IC50 was determined from the concentration-response curve and reported with
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error of the fit. Computation was performed using GraphPad Prism 5 (GraphPad Software, La Jolla,
CA, USA).
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